Paper8595151
Aromatase inhibitors--where are we now?
Miller WR. Br J Cancer, 1996. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Aromatase inhibitors--where are we now? Papers, record 8595151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8595151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Aromatase Inhibitors | Major topic |
| Breast Neoplasms | Major topic |
| Enzyme Inhibitors | Major topic |
| Neoplasms | Major topic |
| Female | |
| Humans |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4811847 | Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria. | Br Med J | 1974 | https://conductscience.org/library/papers/4811847 | PubMed |
| 2 | 7873457 | Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. | Ann Oncol | 1994 | https://conductscience.org/library/papers/7873457 | PubMed |
| 3 | 6213633 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. | J Clin Endocrinol Metab | 1982 | https://conductscience.org/library/papers/6213633 | PubMed |
| 4 | 2527597 | Aromatase inhibitors in the treatment of advanced breast cancer. | Cancer Treat Rev | 1989 | https://conductscience.org/library/papers/2527597 | PubMed |
| 5 | 2369789 | Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2369789 | PubMed |
| 6 | 2278830 | Endocrine treatment for breast cancers: biological rationale and current progress. | J Steroid Biochem Mol Biol | 1990 | https://conductscience.org/library/papers/2278830 | PubMed |
| 7 | 8386541 | The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. | J Steroid Biochem Mol Biol | 1993 | https://conductscience.org/library/papers/8386541 | PubMed |
| 8 | 8240982 | Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells. | J Steroid Biochem Mol Biol | 1993 | https://conductscience.org/library/papers/8240982 | PubMed |
| 9 | 7949208 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. | Breast Cancer Res Treat | 1994 | https://conductscience.org/library/papers/7949208 | PubMed |
| 10 | 7954417 | Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. | Cancer Res | 1994 | https://conductscience.org/library/papers/7954417 | PubMed |
| 11 | 7955367 | Recent advances in biochemical markers of bone turnover. | Clin Chem | 1994 | https://conductscience.org/library/papers/7955367 | PubMed |
| 12 | 7833101 | Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. | Eur J Cancer | 1994 | https://conductscience.org/library/papers/7833101 | PubMed |
| 13 | 7697604 | Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. | Cancer | 1995 | https://conductscience.org/library/papers/7697604 | PubMed |
| 14 | 7749129 | Aromatase inhibitor development for treatment of breast cancer. | Breast Cancer Res Treat | 1995 | https://conductscience.org/library/papers/7749129 | PubMed |
| 15 | 9815984 | Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. | Clin Cancer Res | 1995 | https://conductscience.org/library/papers/9815984 | PubMed |
| 16 | 6797571 | Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. | Br Med J (Clin Res Ed) | 1981 | https://conductscience.org/library/papers/6797571 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 26294292 | Elevated incidence of fractures in women with invasive breast cancer. | Osteoporos Int | 2016 | https://conductscience.org/library/papers/26294292 | PubMed |
| 25429284 | Estrogen biosynthesis and action in ovarian cancer. | Front Endocrinol (Lausanne) | 2014 | https://conductscience.org/library/papers/25429284 | PubMed |
| 10917548 | Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. | Br J Cancer | 2000 | https://conductscience.org/library/papers/10917548 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8595151
GET https://conductscience.org/api/papers/v1/8595151/authors